C4 Therapeutics, Inc. — Director's Dealing 2021

Jun 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-06-14

Reporting Person: COHEN ALAIN J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-14	Common Stock	J	61877	$0.00	Acquired	62143	Direct
2021-06-14	Common Stock	J	22598	$0.00	Acquired	1741930	Indirect

Footnotes

F1: Represents the receipt of shares by the Reporting Person pursuant to pro rata distributions-in-kind, without consideration, of shares of the company's common stock effected on June 14, 2021 by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures") to the partners of Cobro Ventures and by its general partner, Cobro Ventures Fund GP, LLC. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: Shares held by the Reporting Person as trustee of the Alain J. Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.